A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
30actual
Sites
1
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-19 | actual | When the study began enrolling |
| Primary completion | 2025-02-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-24 | actual | The whole study's end, after follow-up |
| First posted | 2023-11-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Skin Quality Deficit
Intervention
- Device: ELAPR002f Injectable Gel
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Achieving Responder Status Based on Evaluating Investigator's Live Assessment of Each Cheek Separately Using Allergan Cheek Smoothness Scale (ACSS)
measured Up to 8 months
Percentage of Participants Achieving Responder Status Based on Evaluating Investigator's Live Assessment of Each Cheek Using Allergan Fine Line Scale (AFLS)
measured Up to 8 months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed